Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLG | P54098 | 2/20 | 0.51 |
| ▸ | TGM2 | P21980 | 1/20 | 0.51 |
| ▸ | PNP | P00491 | 1/20 | 0.49 |
| ▸ | KRAS | P01116 | 2/20 | 0.48 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 3/20 | 0.48 |
| ▸ | P2RY6 | Q15077 | 2/20 | 0.47 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.47 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.47 |
| ▸ | NT5E | P21589 | 1/20 | 0.46 |
| ▸ | POLA1 | P09884 | 1/20 | 0.44 |
| ▸ | P2RX3 | P56373 | 4/20 | 0.44 |
| ▸ | DCPS | Q96C86 | 1/20 | 0.42 |
| ▸ | P2RX1 | P51575 | 3/20 | 0.41 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.41 |
| ▸ | P2RX4 | Q99571 | 2/20 | 0.41 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.41 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.41 |
| ▸ | P2RY11 | Q96G91 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16647568 | 0.94 | TGM2 (0.49) | POLGTGM2PNPKRASFUT5 | |
| SCHEMBL16368348 | 0.94 | TGM2 (0.49) | POLGTGM2PNPKRASFUT5 | |
| SCHEMBL17357557 | 0.90 | IMPDH2 (0.42) | POLGTGM2PNPKRASFUT5 | |
| SCHEMBL4410921 | 0.87 | TGM2 (0.55) | POLGTGM2PNPKRASFUT5 | |
| SCHEMBL4076696 | 0.86 | POLG (0.53) | POLGTGM2PNPKRASFUT5 | |
| SCHEMBL4381958 | 0.86 | POLG (0.53) | POLGTGM2PNPKRASFUT5 | |
| SCHEMBL309062 | 0.85 | TGM2 (0.53) | POLGTGM2PNPKRASFUT5 | |
| SCHEMBL401417 | 0.85 | TGM2 (0.53) | POLGTGM2PNPKRASFUT5 | |
| SCHEMBL30301189 | 0.85 | TGM2 (0.53) | POLGTGM2PNPKRASFUT5 | |
| SCHEMBL8435629 | 0.85 | POLG (0.51) | POLGTGM2PNPKRASFUT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119431453-A | Phosphorus (V) based reagent, method for the production thereof, and use thereof for producing stereoregular organic phosphorus (V) compounds | 百时美施贵宝公司 | 2025-02-14 | — | — | CN | disclosed |
| US-10307439-B2 | Substituted nucleosides, nucleotides and analogs thereof | ALIOS BIOPHARMA, INC. (US) | 2019-06-04 | — | — | US | disclosed |
| US-20170143749-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Biopharma, Inc. | 2017-05-25 | — | — | US | disclosed |
| US-20170143749-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Biopharma, Inc. | 2017-05-25 | — | — | US | disclosed |
| US-20150366888-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Pharmaceuticals, Inc. | 2015-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10307439-B2 | Substituted nucleosides, nucleotides and analogs thereof | PNP, NT5C3B, TYMP | POLG 956/4885TGM2 938/4885PNP 1/4885 |
| US-20150366888-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NT5C3B, TYMP | POLG 956/4885TGM2 938/4885PNP 1/4885 |
| US-20170143749-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NT5C3B, TYMP | POLG 956/4885TGM2 938/4885PNP 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.